Attenuation of Nitrogen Mustard-Induced Pulmonary Injury and Fibrosis by Anti-Tumor Necrosis Factor-α Antibody

被引:50
|
作者
Malaviya, Rama [1 ]
Sunil, Vasanthi R. [1 ]
Venosa, Alessandro [1 ]
Verissimo, Vivianne L. [1 ]
Cervelli, Jessica A. [1 ]
Vayas, Kinal N. [1 ]
Hall, LeRoy [3 ]
Laskin, Jeffrey D. [2 ]
Laskin, Debra L. [1 ]
机构
[1] Rutgers State Univ, Dept Pharmacol & Toxicol, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA
[2] Rutgers State Univ, Dept Environm & Occupat Med, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA
[3] Janssen Res & Dev, Dept Drug Safety Sci, Raritan, NJ 08869 USA
基金
美国国家卫生研究院;
关键词
alveolar macrophages; lung injury; vesicant; fibrosis; ACUTE LUNG INJURY; SULFUR MUSTARD; MACROPHAGE ACTIVATION; TISSUE-INJURY; MURINE MODEL; TNF-ALPHA; INFLAMMATION; EXPRESSION; MECHANISMS; RECEPTOR;
D O I
10.1093/toxsci/kfv161
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Nitrogen mustard (NM) is a bifunctional alkylating agent that causes acute injury to the lung that progresses to fibrosis. This is accompanied by a prominent infiltration of macrophages into the lung and upregulation of proinflammatory/profibrotic cytokines including tumor necrosis factor (TNF)alpha. In these studies, we analyzed the ability of anti-TNF alpha antibody to mitigate NM-induced lung injury, inflammation, and fibrosis. Treatment of rats with anti-TNF alpha antibody (15 mg/kg, iv, every 9 days) beginning 30 min after intratracheal administration of NM (0.125 mg/kg) reduced progressive histopathologic alterations in the lung including perivascular and peribronchial edema, macrophage/monocyte infiltration, interstitial thickening, bronchiolization of alveolar walls, fibrin deposition, emphysema, and fibrosis. NM-induced damage to the alveolar-epithelial barrier, measured by bronchoalveolar lavage (BAL) protein and cell content, was also reduced by anti-TNF alpha antibody, along with expression of the oxidative stress marker, heme oxygenase-1. Whereas the accumulation of proinflammatory/cytotoxic M1 macrophages in the lung in response to NM was suppressed by anti-TNF alpha antibody, antiinflammatory/profibrotic M2 macrophages were increased or unchanged. Treatment of rats with anti-TNF alpha antibody also reduced NM-induced increases in expression of the profibrotic mediator, transforming growth factor-beta. This was associated with a reduction in NM-induced collagen deposition in the lung. These data suggest that inhibiting TNF alpha may represent an efficacious approach to mitigating lung injury induced by mustards.
引用
收藏
页码:71 / 88
页数:18
相关论文
共 50 条
  • [41] Population Pharmacokinetics of Golimumab, an Anti-Tumor Necrosis Factor-α Human Monoclonal Antibody, in Patients With Psoriatic Arthritis
    Xu, Zhenhua
    Vu, Thuy
    Lee, Howard
    Hu, Chuanpu
    Ling, Jie
    Yan, Hong
    Baker, Daniel
    Beutler, Anna
    Pendley, Charles
    Wagner, Carrie
    Davis, Hugh M.
    Zhou, Honghui
    JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (09): : 1056 - 1070
  • [42] Generation of a Human Anti-Tumor Necrosis Factor-α Monoclonal Antibody by in Vitro Immunization with a Multiple Antigen Peptide
    Fujiki, Tsukasa
    Tsuji, Atsuji
    Matsumoto, Shin-ei
    Yamashita, Makiko
    Teruya, Kiichiro
    Shirahata, Sanetaka
    Katakura, Yoshinori
    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2010, 74 (09) : 1836 - 1840
  • [43] Pulmonary Artery Perfusion with Anti-Tumor Necrosis Factor Alpha Antibody Reduces Cardiopulmonary Bypass-Induced Inflammatory Lung Injury in a Rabbit Model
    Yu, Yang
    Gao, Mingxin
    Li, Haitao
    Zhang, Fan
    Gu, Chengxiong
    PLOS ONE, 2013, 8 (12):
  • [44] Anti-Tumor Necrosis Factor-α Treatment with Infliximab for Disseminated Granuloma Annulare
    Murdaca, Giuseppe
    Colombo, Barbara Maria
    Barabino, Gianfranco
    Caiti, Matteo
    Cagnati, Paola
    Puppo, Francesco
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2010, 11 (06) : 437 - 439
  • [45] Sex hormone binding globulin and anti-tumor necrosis factor-α therapy
    Aydin, Banu Kucukemre
    Winters, Stephen J.
    JOURNAL OF PEDIATRICS, 2016, 177 : 334 - 334
  • [46] Should anti-tumor necrosis factor-α be the first therapy for rheumatoid vasculitis?
    Garcia-Porrua, C
    Gonzalez-Gay, MA
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (02) : 433 - 433
  • [47] Atopic dermatitis as a side effect of anti-tumor necrosis factor-α therapy
    Mangge, H
    Gindl, S
    Kenzian, H
    Schauenstein, K
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (11) : 2506 - 2507
  • [48] Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-α therapy
    Yee, AMF
    Pochapin, MB
    ANNALS OF INTERNAL MEDICINE, 2001, 135 (01) : 27 - 31
  • [49] Bullous pemphigoid occurring under anti-tumor necrosis factor-α therapy
    M. Ricci
    Stefania Zauli
    A. Zelante
    L. Trevisani
    A. Virgili
    V. Bettoli
    International Journal of Colorectal Disease, 2014, 29 : 1573 - 1574
  • [50] Inverse responses of the skin and nail lesions of psoriatic arthritis to an anti-interleukin-17A antibody and an anti-tumor necrosis factor-α antibody
    Komatsu-Fujii, Takayoshi
    Honda, Tetsuya
    Otsuka, Atsushi
    Kabashima, Kenji
    JOURNAL OF DERMATOLOGY, 2019, 46 (11): : E440 - E441